RT Journal Article
T1 Early neuromodulation prevents the development of brain and behavioral abnormalities in a rodent model of schizophrenia
A1 Hadar, R.
A1 Bikovski, L.
A1 Soto Montenegro, Mª Luisa
A1 Schimke, J.
A1 Maier, P.
A1 Ewing, S.
A1 Voget, M.
A1 Wieske, Franziska
A1 Goetz, T.
A1 Desco Menéndez, Manuel
A1 Hamani, Clement
A1 Pascau González-Garzón, Javier
A1 Weiner, Ina
A1 Winter, Christine
AB The notion that schizophrenia is a neurodevelopmental disorder in which neuropathologies evolve gradually over thedevelopmental course indicates a potential therapeutic window during which pathophysiological processes may be modified tohalt disease progression or reduce its severity. Here we used a neurodevelopmental maternal immune stimulation (MIS) rat modelof schizophrenia to test whether early targeted modulatory intervention would affect schizophrenia’s neurodevelopmental course.We applied deep brain stimulation (DBS) or sham stimulation to the medial prefrontal cortex (mPFC) of adolescent MIS rats andrespective controls, and investigated its behavioral, biochemical, brain-structural and -metabolic effects in adulthood. We foundthat mPFC-DBS successfully prevented the emergence of deficits in sensorimotor gating, attentional selectivity and executivefunction in adulthood, as well as the enlargement of lateral ventricle volumes and mal-development of dopaminergic andserotonergic transmission. These data suggest that the mPFC may be a valuable target for effective preventive treatments. This mayhave significant translational value, suggesting that targeting the mPFC before the onset of psychosis via less invasiveneuromodulation approaches may be a viable preventive strategy.
PB Springer Nature
SN 1359-4184
YR 2017
FD 2017-04-04
LK https://hdl.handle.net/10016/32900
UL https://hdl.handle.net/10016/32900
LA eng
NO We thank Renate Winter, Doris Zschaber and Roselies Pickert for excellent technicalassistance. This research was conducted under the EraNet Neuron framework(DBS_F20rat) and supported by the BMBF, Germany (B01EW1103, 01EE1403A),Fundación Mapfre, Comunidad de Madrid and the Ministry of Economy andCompetitiveness ISCIII-FIS grants (PI14/00860, CPII/00005) co-financed by ERDF (FEDER) Funds from the European Commission, ‘A way of making Europe’, Spain (PI14/00860, CPII/00005, MV1500002), the CSO-MOH, Israel (3-8580) and the CanadianInstitutes of Health Research, Canada (CIHR, 110068), and co-financed by the DFG,Germany (WI 2140/1-1/2; WI 2140/2-1).
DS e-Archivo
RD 11 sept. 2024